Treatment of Wegener’s Granulomatosis

  • Lutz Briedigkeit
  • Marianne Ulmer
  • Ursula Göbel
  • Rudolf Natusch
  • Eva Reinhold-Keller
  • Wolfgang L. Gross
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 336)

Summary

Treatment and outcome of 111 patients who fell ill with Wegener’s granulomatosis (WG) between 1966 and 1990 were analysed retrospectively. Two regimens of treatment were distinguished: “conventional” treatment, i.e. daily application of cyclophosphamide/corticosteroids (FAUCI scheme) or azathioprine/ corticosteroids or corticosteroids alone, and “stage-adapted” treatment, characterized by change of different treatments (e.g. cyclophosphamide pulse therapy, cotrimoxazole) according to the extent and activity of disease. In patients who received stage-adapted treatment, exacerbations occurred significantly more frequent than in conventionally treated patients, while lethal outcome was much more frequent in conventionally treated patients.

Keywords

Complete Remission Lupus Nephritis Partial Remission Renal Complication Lethal Outcome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Austin, H. A., Klippel, J. H., Balow, J. E. et al., 1986, Therapy of lupus nephritis, N Engl. J Med. 314: 614–619PubMedCrossRefGoogle Scholar
  2. De Remee, R. A., McDonald, T. J., and Weiland, L. H., 1985, Wegener’s granulomatosis: observations on treatment with antimicrobial agents, Mayo. Clin. Proc. 60: 27–32CrossRefGoogle Scholar
  3. Fauci, A. S., Haynes, B. F., Katz, P. et al., 1983, Wegener’s granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years, Ann. Intern. Med. 98: 76–85PubMedCrossRefGoogle Scholar
  4. Georgi, J., Reinhold-Keller, E., and Gross, W. L., 1991, Cotrimoxazol bei Wegenerscher Granulomatose - Ergebnisse einer prospektiven Studie. Z. Rheumatol. 50: 249Google Scholar
  5. Godman, G. and Churg, J., 1954, Wegener’s granulomatosis: pathology and a review of the literature, Arch. Pathol. 58: 533–553Google Scholar
  6. Leavitt, R. Y., Fauci, A. S., Bloch, D. A. et al., 1990, The American College of Rheumatology 1990 criteria for the classification of Wegener’s granulomatosis, Arthritis Rheum. 33: 1101–1107PubMedCrossRefGoogle Scholar
  7. Le Thi Huong Du, Wechsler, S., de Gennes, C. et al., 1989, Aspects évoluties et prognostiques de la granulomatose de Wegener, Revue du Rhumatisme56: 583–588Google Scholar
  8. Reinhold-Keller, E., Ulmer, M., Georgi, J. et al., 1991, Cyclophosphamid-Stoßtherapie bei der Wegenerschen Granulomatose: Prospektive Studie, Kiln. Wochenschr. 69 ( Suppl. XXIII ): 240–241Google Scholar
  9. Steppat, D. and Gross, W. L., 1989, Stage-adapted treatment of Wegener’s granulomatosis, Klin. Wochenschr. 67: 666–671PubMedCrossRefGoogle Scholar
  10. Van der Woude, F. J., Lobatto, S., Permin, H. et al., 1985, Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener’s granulomatosis, Lancet I: 425–429PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1993

Authors and Affiliations

  • Lutz Briedigkeit
    • 1
  • Marianne Ulmer
    • 2
  • Ursula Göbel
    • 1
  • Rudolf Natusch
    • 1
  • Eva Reinhold-Keller
    • 2
  • Wolfgang L. Gross
    • 2
  1. 1.1st Medical DepartmentBerlin-Buch Clinical CenterBerlinGermany
  2. 2.Department of Rheumatology and Rheumaklinik Bad Bramstedt GmbH, Medical DepartmentMedical University of LübeckBad BramstedtGermany

Personalised recommendations